In a patient with suspected systemic lupus erythematosus and recurrent miscarriages, is it safe to start hydroxychloroquine now and continue it throughout pregnancy?

Hydroxychloroquine in SLE with Recurrent Miscarriage

Yes, you should start hydroxychloroquine now and continue it throughout pregnancy—this is both safe and beneficial for reducing lupus flares and improving pregnancy outcomes. 1

Starting Hydroxychloroquine Before Pregnancy

• If the patient is not currently on HCQ, start it now before pregnancy is achieved, as the 2020 ACR guidelines conditionally recommend initiating HCQ in SLE patients planning pregnancy if there are no contraindications 1
• If already on HCQ, strongly continue it without interruption, as discontinuation significantly increases disease activity and flare risk 1
• The goal is to achieve disease quiescence before conception, which substantially improves maternal and fetal outcomes 1

Continuation Throughout Pregnancy

HCQ should be maintained throughout the entire pregnancy based on strong guideline recommendations and extensive safety data 1:

• The 2020 ACR guidelines strongly recommend continuing HCQ during pregnancy if already taking it 1
• The 2017 EULAR recommendations state that "hydroxychloroquine is beneficial during pregnancy to reduce the risk of SLE flares and of poor obstetrical outcomes" 1
• Multiple studies demonstrate HCQ reduces lupus activity during pregnancy without fetal harm 2, 3

Safety Profile in Pregnancy

The FDA label and clinical evidence confirm excellent safety 4:

• No increased risk of major birth defects, miscarriage, or adverse maternal/fetal outcomes based on decades of clinical experience 4
• No retinal toxicity, ototoxicity, cardiotoxicity, or developmental abnormalities observed in children exposed to HCQ in utero 4
• HCQ crosses the placenta but cord blood levels corresponding to maternal levels have not been associated with fetal harm 4

Specific Benefits for This Patient

For SLE with recurrent miscarriage, HCQ provides multiple advantages:

• Reduces lupus flare risk during pregnancy, which is critical since active disease increases adverse pregnancy outcomes including spontaneous abortion, fetal death, preeclampsia, and preterm birth 4
• Decreases preeclampsia risk by approximately 51% (adjusted risk ratio 0.49,95% CI 0.31-0.79) 5
• Lowers rates of gestational hypertension (OR 0.41,95% CI 0.19-0.89) and prematurity (OR 0.55,95% CI 0.36-0.86) 6
• A 2022 meta-analysis of 668 pregnancies showed HCQ decreased highly active lupus without harm to pregnancy outcomes 2

Dosing Recommendations

• Target dose: 5 mg/kg/day based on actual body weight 1
• Recent evidence shows reducing below 5 mg/kg/day increases moderate-to-severe flare risk (OR 6.04) and lupus-related hospitalizations (aOR 4.2) 7
• Adjust for renal impairment if present 1

Additional Management Considerations

Beyond HCQ, this patient requires:

• Test for antiphospholipid antibodies (LAC, aCL, anti-β2GPI) once before or early in pregnancy, as these are major risk factors for recurrent pregnancy loss 1
• Add low-dose aspirin 81-100 mg daily starting in the first trimester, as SLE patients are at high risk for preeclampsia 1
• Monitor disease activity with clinical assessment and laboratory tests (CBC, urinalysis, anti-dsDNA, C3, C4) at least once per trimester 1

Critical Pitfall to Avoid

Never discontinue HCQ during pregnancy—cessation increases lupus activity significantly, with flare rates up to 6 times higher and a 31.3% relapse rate versus 12.5% in adherent patients 3, 7. Women who stopped HCQ had higher lupus activity scores and required higher prednisone doses during pregnancy 3.

Contraindications

The only contraindications to HCQ are allergy, severe adverse effects, or documented intolerance 1. Pregnancy itself is not a contraindication—in fact, untreated SLE poses greater risks to both mother and fetus than HCQ exposure 4.